论文部分内容阅读
异基因外周血造血干细胞移植是目前能够治愈急性白血病的最佳方法,随着国内独生子女家庭的日益增多,同胞供体减少,从中华骨髓库中检索配型全相合造血干细胞供者概率较低,耗时长,而单倍体造血干细胞移植如能成功开展将是解决供者来源困难的主要手段,但其面临植入困难和移植物抗宿主病发生率高且重这两大风险。通过改良预处理方案及在经典的环孢素A+短程甲氨蝶呤的基础上,加用霉酚酸脂、白细胞介素11、抗人淋巴细胞免疫球蛋白及经重组人粒细胞集落刺激因子动员后的供体造血干细胞输注给受体联合预防移植物抗宿主病,成功的进行了2例单倍体外周血造血干细胞移植,2例患者均顺利植入,且无严重的移植物抗宿主病。
Allogeneic peripheral blood stem cell transplantation is the best way to cure acute leukemia. With the increasing number of only-child families in China and fewer sibling donors, the probability of searching matched full-matched hematopoietic stem cell donors from China's bone marrow bank is lower , Which takes a long time. However, haploidentical hematopoietic stem cell transplantation, if successfully carried out, will be the main means to solve the problem of donor source. However, it faces the two major risks of implants and graft-versus-host disease. Based on the modified cyclosporine A + short-course methotrexate, mycophenolate mofetil, interleukin 11, anti-human lymphocyte immunoglobulin and recombinant human granulocyte colony-stimulating factor After mobilization of donor hematopoietic stem cells infused into recipients to prevent graft-versus-host disease, two haploid peripheral blood stem cell transplants were successfully performed, and two patients were successfully implanted without serious graft-versus-graft Host disease.